NCT Number: NCT00122863
Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder
This is a clinical trial assessing the time to relapse of anxiety symptoms among patients with generalized anxiety disorder who have responded to duloxetine therapy.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients presenting with generalized anxiety disorder (GAD) in the absence of major depressive disorder (MDD). Patients must suffer from GAD and not from an adjustment disorder or anxiety disorder not otherwise specified (NOS). Symptoms of GAD should not be situational in nature.
Exclusion criteria
- Any current and primary diagnosis other than GAD. Patients diagnosed with or who have a history of MDD within the past 6 months OR patients diagnosed with or who have a history of panic disorder, post-traumatic stress disorder (PTSD), or an eating disorder within the past year OR patients who have been diagnosed with obsessive- compulsive disorder (OCD), bipolar affective disorder, psychosis, factitious disorder or somatoform disorders during their lifetime.
- History of alcohol or any psychoactive substance abuse of dependence (as defined in the DSM-IV-TR) within the past 6 months
- Serious medical illness, including cardiovascular, hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic disease, or clinically significant laboratory abnormality that is not stabilized or is anticipated to require hospitalization within 6 months, in the opinion of the investigator. Clinically significant laboratory abnormalities are those, that, in the judgement of the investigator, indicate a serious medical problem.
- Acute liver injury (such as hepatitis) or severe cirrhosis (Child- Pugh Class C)
Treatment and study plan
Placebo
DrugPrimary outcomes
-
Assess the long-term maintenance of efficacy of duloxetine 60 to 120 mg QD compared with placebo by a comparison of the time to relapse among patients with GAD who responded to duloxetine during the open-label acute therapy phase after 22 to 26 weeks.
Secondary outcomes
-
Self-reported anxiety symptomatology
-
Pain
-
Quality of Life
-
Clinical Global Improvement and HAMA Factor scores
-
Maintenance of Effect
Sponsors and collaborators
Lead sponsor
Eli Lilly and Company
Industry
Collaborators
- Boehringer Ingelheim
Registry information
Official study title
Duloxetine 60 to 120 mg Once Daily Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder
Important dates
- Study start
- 2005
- Study completion
- 2007
- First posted
- Jul 22, 2005
- Registry last updated
- Aug 31, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Process and Outcomes in CBT for Anxious and Depressed Youth
NCT03100279
Anxiety Disorders, Behavior
Piscataway, New Jersey, United States
View Trial DetailsTransdiagnostic Behavioral Activation Therapy for Youth Anxiety and Depression
NCT01829100
Anxiety Disorders, Depressive Disorder
Piscataway, New Jersey, United States
View Trial DetailsTesting a Transdiagnostic TMS Treatment Target
NCT06282146
Anxiety Disorders, Behavior
Boston, Massachusetts, United States
View Trial DetailsFeasibility and Acceptability of Problem Management Plus (PM+) for Prisoners in the Netherlands - a Pilot RCT
NCT05927987
Anxiety Disorders, Depressive Disorder
Amsterdam, Netherlands
View Trial Details